Toll-interleukin 1 receptor domain-containing adapter protein (TIRAP)

Toll-interleukin 1 receptor domain-containing adapter protein (TIRAP), also known as Mal, is a crucial adapter molecule that mediates signaling for the innate immune system. It acts as a bridge specifically for Toll-like receptors 2 (TLR2) and 4 (TLR4), recruiting the MyD88 adapter to the plasma membrane to initiate downstream signaling cascades such as NF-kappaB and MAPK [UniProt, PubMed]. This activation leads to the production of pro-inflammatory cytokines necessary for an effective immune response against pathogens like bacteria and fungi [PubMed]. TIRAP is considered a significant therapeutic target because its overactivation is linked to the cytokine storm seen in sepsis and various chronic inflammatory or autoimmune conditions [NIH]. While there are currently no FDA-approved drugs targeting TIRAP, experimental strategies include using small molecule inhibitors, decoy peptides, and RNA interference (siRNA) targeting TIRAP mRNA to modulate hyper-inflammation [Peer-reviewed journals]. Additionally, the S180L genetic polymorphism in the TIRAP gene is a well-documented biomarker that influences an individual's susceptibility to multiple infectious diseases, including malaria and tuberculosis [Nature, PubMed].

Other names

MalMyD88-adapter-like proteinTIR domain-containing adapter proteinWyattTIRAP

Inhibition of the recruitment of MyD88 to Toll-like receptors 2 and 4 at the plasma membrane, thereby preventing the activation of NF-kappaB and MAPK signaling pathways and reducing the production of pro-inflammatory cytokines.